Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyllis I Spuls

Showing results (41-50 of 126) with videos related to

Pageof 13
Sort By:
Journal of the American Academy of Dermatology|October 9, 2016
Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the fieldJanny E Lommerts, Hansje-Eva Teulings, Khaled Ezzedine, et al.
The Journal of Dermatological Treatment|April 26, 2023
The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort studyAngela L Bosma, Louise A A Gerbens, Hajar El Khattabi, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trialsJochen Schmitt, Phyllis I Spuls, Kim S Thomas, et al.
The Journal of Investigative Dermatology|June 20, 2014
The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cellsMarcel B M Teunissen, Nataliya G Yeremenko, Dominique L P Baeten, et al.
Therapeutic Drug Monitoring|May 21, 2019
Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on UstekinumabEline De Keyser, Celine I Busard, Sven Lanssens, et al.
BMJ Open|August 31, 2018
Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysisAaron Mark Drucker, Alexandra Ellis, Zarif Jabbar-Lopez, et al.
Archives of Dermatology|June 24, 2004
Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporineBrent C Opmeer, Vera M R Heydendael, Corianne A J M De Borgie, et al.
The Journal of Dermatological Treatment|December 21, 2023
The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic reviewAnouk G M Caron, Manja Bloem, Hajar El Khattabi, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 11, 2011
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in menAnja Blumeyer, Antonella Tosti, Andrew Messenger, et al.
Journal of the American Academy of Dermatology|March 6, 2021
Response to: "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'"Angela L Bosma, Linde E M de Wijs, Michel H Hof, et al.
Pageof 13

Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Journal of the American Academy of Dermatology|October 9, 2016
Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the fieldJanny E Lommerts, Hansje-Eva Teulings, Khaled Ezzedine, et al.
The Journal of Dermatological Treatment|April 26, 2023
The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort studyAngela L Bosma, Louise A A Gerbens, Hajar El Khattabi, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trialsJochen Schmitt, Phyllis I Spuls, Kim S Thomas, et al.
The Journal of Investigative Dermatology|June 20, 2014
The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cellsMarcel B M Teunissen, Nataliya G Yeremenko, Dominique L P Baeten, et al.
Therapeutic Drug Monitoring|May 21, 2019
Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on UstekinumabEline De Keyser, Celine I Busard, Sven Lanssens, et al.
BMJ Open|August 31, 2018
Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysisAaron Mark Drucker, Alexandra Ellis, Zarif Jabbar-Lopez, et al.
Archives of Dermatology|June 24, 2004
Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporineBrent C Opmeer, Vera M R Heydendael, Corianne A J M De Borgie, et al.
The Journal of Dermatological Treatment|December 21, 2023
The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic reviewAnouk G M Caron, Manja Bloem, Hajar El Khattabi, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 11, 2011
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in menAnja Blumeyer, Antonella Tosti, Andrew Messenger, et al.
Journal of the American Academy of Dermatology|March 6, 2021
Response to: "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'"Angela L Bosma, Linde E M de Wijs, Michel H Hof, et al.
Pageof 13